# KEYNOTE-522 (NCT03036488)

> Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03036488
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Triple Negative Breast Neoplasms
- Interventions: Pembrolizumab; Carboplatin; Paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide; Placebo; Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
- Enrollment: 1174
- Primary outcome: Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery
- Primary outcome: Event-free Survival (EFS) as assessed by Investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 290
- YouTube: 199
- Podcasts: 156
- X videos: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-522-nct03036488

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03036488", "email": "<work email>"}; the inbox owner confirms by the emailed link.